grant

Advancing gastric cancer precision medicine in Latinos through patient-derived modeling

Organization UNIVERSITY OF CALIFORNIA AT DAVISLocation DAVIS, UNITED STATESPosted 1 Aug 2023Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY20251-Phosphatidylinositol 3-KinaseAddressAfrican AmericanAfro AmericanAfroamericanAssayBioassayBiological AssayCTEPCaliforniaCancer BurdenCancer CauseCancer EtiologyCancer ModelCancer PatientCancer Therapy Evaluation ProgramCancer TreatmentCancerModelCancersCaucasian FemalesCaucasian WomenCaucasian maleCaucasian menCell CycleCell Division CycleChemotherapy ProtocolChemotherapy RegimenChemotherapy-Oncologic ProcedureClinical ResearchClinical StudyClinical TrialsCollectionCombination Chemotherapy RegimenComplexComprehensive Cancer CenterDNA mutationDataDeath RateDevelopmentDiagnosisDisparitiesDisparityDrug CombinationsDrug ModelingsDrugsEthnic GroupEthnic OriginEthnic PeopleEthnic PopulationEthnic individualEthnicityEthnicity PeopleEthnicity PopulationEuropeanFDA approvedFK506 Binding Protein 12-Rapamycin Associated Protein 1FKBP12 Rapamycin Complex Associated Protein 1FRAP1FRAP1 geneFRAP2FrequenciesFundingGastric Body CancerGastric CancerGastric Cardia CancerGastric Fundus CancerGastric NeoplasmsGastric Pylorus CancerGastric TumorGenerationsGenesGeneticGenetic ChangeGenetic defectGenetic mutationGenomeGenomicsGoalsHigh PrevalenceIn VitroIncidenceIndigenous AmericanIndividuals from minorityIndividuals of minorityInfrastructureInvestigatorsKinasesKnowledgeLatina PopulationLatina femalesLatina womenLatina/e womenLatina/x womenLatinasLatine femalesLatine womenLatinoLatino PopulationLatino femalesLatino groupLatino individualLatino maleLatino menLatino peopleLatino womenLatinosLatinx femalesLatinx manLatinx menLatinx womenLung NeoplasmsLung TumorMalignant Gastric NeoplasmMalignant Gastric TumorMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMechanistic Target of RapamycinMedicationMedicineMinorityMinority GroupsMinority PeopleMinority PopulationMinority individualModelingMolecular TargetMutateMutationNational Cancer BurdenOrganoidsPDX modelPI-3 KinasePI-3K/AKTPI3-KinasePI3CGPI3K-AlphaPI3K/AKTPI3KGammaPI3kPIK3PIK3-AlphaPIK3CAPIK3CA genePIK3CGPIK3CG genePTK ReceptorsPathway interactionsPatient derived xenograftPatientsPatternPharmaceutical PreparationsPhosphatidylinositol 3-KinasePhosphatidylinositol 3-Kinase, Catalytic, 110-kD, AlphaPhosphatidylinositol 3-Kinase, Catalytic, AlphaPhosphatidylinositol-3-OH KinasePhosphoinositide 3-HydroxykinasePhosphotransferase GenePhosphotransferasesPopulationPtdIns 3-KinasePulmonary NeoplasmsQuimioterapiaRAFT1RaceRacesRacial GroupReceptor Protein-Tyrosine KinasesReceptor Tyrosine Kinase GeneResearchResearch PersonnelResearchersResistanceSignal PathwaySomatic MutationStomach CancerStomach NeoplasmsStomach TumorTCGATestingTexasThe Cancer Genome AtlasTranslatingTranslational ResearchTranslational ScienceTransmembrane Receptor Protein Tyrosine KinaseTransphosphorylasesType I Phosphatidylinositol KinaseType III Phosphoinositide 3-KinaseTyrosine Kinase Linked ReceptorsTyrosine Kinase ReceptorsUniversitiesWhite FemalesWhite WomenWorkanti-cancer therapycancer cell genomecancer chemotherapycancer disparitycancer genomecancer genomicscancer health disparitycancer therapycancer typecancer-directed therapycancer-related health disparitycandidate biomarkercandidate identificationcandidate markerchemotherapydepositorydevelopmentaldisparities in mortalitydisparity in cancerdrug/agentethnic minorityethnic subgroupethnicity groupexome sequencingexome-seqexpression subtypesgastric malignancygenome mutationgenomic datagenomic datasethigh riskin vivoindividualized cancer careindividualized oncologyinhibitorkinase inhibitorlatinx malemTORmalignancymalignant stomach neoplasmmalignant stomach tumormammalian target of rapamycinminority patientmolecular sub-typesmolecular subsetsmolecular subtypesmortalitymortality disparitymortality ratemortality ratiomutantneoplasm/cancernew drug combinationnew drug treatmentsnew drugsnew pharmacological therapeuticnew pharmacotherapy combinationnew therapeuticsnew therapynext generation therapeuticsnovel drug combinationnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy combinationnovel therapeuticsnovel therapyoncogenomicsp110-Alphapathwaypatient derived xenograft modelpatients from minoritypatients of minoritypersonalized oncologypre-clinicalprecision cancer careprecision cancer medicineprecision medicineprecision oncologyprecision-based medicinepreclinicalracialracial backgroundracial minorityracial originracial populationracial subgrouprepositoryresistantresponseresponse to therapyresponse to treatmentsomatic variantstomach fundus cancerstomach pylorus cancersurvival disparitytargeted cancer therapytargeted drug therapytargeted drug treatmentstargeted drug trialstargeted pharmaceutical trialstargeted therapeutictargeted therapeutic agentstargeted therapytargeted therapy trialstargeted treatmenttargeted treatment trialstherapeutic responsetherapy responsetranslation researchtranslational investigationtreatment responsetreatment responsivenesstumortumor genometumor growthwhite malewhite men
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

PROJECT SUMMARY/ASTRACT
Gastric cancer (GC) is a leading cause of cancer incidence, mortality, and survival disparities in Latinos, the

largest and youngest U.S. minority and the largest racial/ethnic group in the UCaTS states of California and

Texas. When compared to non-Latino whites (NLW), GC incidence and mortality is ~>2-fold higher in…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Advancing gastric cancer precision medicine in Latinos through patient-derived modeling — UNIVERSITY OF CALIFORNIA AT DA | Dev Procure